Anyone know if U of Aukland still owns DMXAA? I saw a note that it started PI in the UK in 1995(!). Is there something wrong with it? (This abstract seems to say not (but I don't understand about dosing and other models.)
Aventis and Shering AG are only 2 pharma competitors in VTA I can find. Is it true--as the company said today on the CC--that it is at least 2 years ahead of next VTA competitor? One of them is in PI.
___________________________
Int J Radiat Biol 2001 Feb;77(2):195-204 Related Articles, Books, LinkOut
Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
Murata R, Overgaard J, Horsman MR.
Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus University Hospital. rumi@oncology.dk
PURPOSE: To compare the ability of combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to change tissue blood perfusion. MATERIALS AND METHODS: The tissues were a C3H mouse mammary carcinoma and various murine normal tissues, with perfusion measured using the 86RbCl extraction technique. RESULTS: CA4DP (250mg/kg; i.p.) reduced tumour perfusion to 34% of that seen in controls within 1 h of injection. It was maintained at this for at least 6 h, returning to control levels by 24 h. This decrease was dose-dependent. DMXAA (25mg/kg; i.p.) caused a 79% reduction in tumour perfusion 6h after injection; no recovery was observed even after 24 h. DMXAA showed no changes at doses below 10 mg/kg. Both CA4DP and DMXAA increased perfusion in the gut, kidney, bladder and lung, while decreasing splenic perfusion. CA4DP tended to decrease perfusion in muscle, while DMXAA increased liver perfusion. These changes in normal tissue perfusion were generally less than those changes seen in tumours. No significant changes were seen in skin. CONCLUSIONS: CA4DP and DMXAA produced a selective and significant reduction in tumour perfusion, but the pattern of change was different. These results suggest how these vascular targeting drugs should be combined with more conventional therapies.
PMID: 11236926 [PubMed - indexed for MEDLINE] |
